Pyxis Oncology (PYXS) Accounts Payables (2020 - 2026)
Pyxis Oncology (PYXS) posted quarterly Accounts Payables of $10.9 million for Q4 2025, up 124.02% year-over-year from $4.9 million in Q4 2024, and up 11.57% quarter-over-quarter from $9.8 million in Q3 2025.
Pyxis Oncology (PYXS) Accounts Payables (2020 - 2026) Analysis & Trends
Pyxis Oncology (PYXS) has reported Accounts Payables for 6 consecutive years, with $10.9 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Accounts Payables rose 124.02% year-over-year to $10.9 million; the TTM figure through Dec 2025 stood at $10.9 million (up 124.02% YoY), while the FY2025 annual figure was $10.9 million, up 124.02% from the prior year.
- Accounts Payables climbed to $10.9 million in Q4 2025 per PYXS's latest filing, from $9.8 million in the prior quarter.
- Across five years, Accounts Payables topped out at $12.0 million in Q4 2021 and bottomed at $1.3 million in Q2 2023.
- Historically, Accounts Payables has averaged $5.5 million across 5 years, with a median of $4.9 million in 2024.
- Annual changes were most pronounced in 2021 — Accounts Payables surged 1009.66% — and 2023, when it slumped 83.31%.
- Pyxis Oncology's Accounts Payables stood at $12.0 million in 2021, then slumped by 40.62% to $7.1 million in 2022, then tumbled by 45.1% to $3.9 million in 2023, then advanced by 24.72% to $4.9 million in 2024, then soared by 124.02% to $10.9 million in 2025.
- Business Quant data shows PYXS's Accounts Payables at $10.9 million in Q4 2025, $9.8 million in Q3 2025, and $9.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Pyxis Oncology | 198.37 Mn | 165.38 Mn | - | 3.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.27 Mn |
| Dec 31, 2025 | 10.89 Mn |
| Sep 30, 2025 | 9.76 Mn |
| Jun 30, 2025 | 9.41 Mn |
| Mar 31, 2025 | 2.85 Mn |
| Dec 31, 2024 | 4.86 Mn |
| Sep 30, 2024 | 4.87 Mn |
| Jun 30, 2024 | 5.47 Mn |
| Mar 31, 2024 | 2.29 Mn |
| Dec 31, 2023 | 3.90 Mn |
| Sep 30, 2023 | 3.31 Mn |
| Jun 30, 2023 | 1.31 Mn |
| Mar 31, 2023 | 4.03 Mn |
| Dec 31, 2022 | 7.10 Mn |
| Sep 30, 2022 | 5.51 Mn |
| Jun 30, 2022 | 7.82 Mn |
| Mar 31, 2022 | 2.06 Mn |
| Dec 31, 2021 | 11.95 Mn |
| Sep 30, 2021 | 1.93 Mn |
| Dec 31, 2020 | 1.08 Mn |